Cancer Therapy Advisor Institute Spotlight Course

The Evolving Landscape of Targeted Therapies for Metastatic Colorectal Cancer: New Frontiers of Personalized Cancer Care

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.00 CME CE: Current, evidence-based recommendations for targeted metastatic colorectal cancer therapies to manage individualized needs. Exp 3/8/24

Improving Outcomes in CAR T-cell Therapy for DLBCL | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.00 CME CE: Patients with DLBCL face poor outcomes with salvage treatments. CAR T-cell therapy shows promise for patients with relapse after chemoimmunotherapy and ASCT. Exp 10/27/23

Importance of an Identified Genetic Alteration in Precision Oncology | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

0.25 CME CE: TSC1 and TSC2 mutations impact the mTOR pathway and may inform mTOR inhibitor use in solid tumors. Learn about how to identify these mutations using next-generation sequencing. Exp 6/28/24

Management of Advanced NSCLC | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

0.75 CME CE: Second-line strategies for advanced NSCLC with angiogenic therapies and combination regimens and managing associated adverse events from a multidisciplinary clinician perspective. Exp 8/14/24

Changing Pharmacological Paradigms for Higher-Risk Myelofibrosis | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.00 CME CE: This course discusses how Individuals with intermediate and high-risk myelofibrosis stand to benefit the most from recently approved and investigational agents. Exp 5/19/24

Advances in MDS Diagnosis and Individualized Treatment | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists

0.50 CME CE: Multimedia journey about the latest updates on the management of higher-risk MDS and the overlap between MDS and AML with mutated TP53. Exp 3/31/24

Clinical Trial Equity in Non-Hodgkin Lymphoma | myCME

AMA PRA Category 1 Credit(s)^TM

1.00 CME: Join a panel discussion on strategies to communicate with patients about the clinical-trial process for Non-Hodgkin Lymphoma. Exp 3/1/24

Importance of an Identified Genetic Alteration in Precision Oncology | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

0.75 CME CE: The number of tumor agnostic biomarkers that inform cancer treatment selection is growing. TSC1 and TSC2 mutations impact the mTOR pathway and may inform mTOR inhibitor use in solid tumors. Exp 6/28/24

Prostate Cancer CME: Optimizing ADT and Improving Outcomes | myCME

AMA PRA Category 1 Credit(s)^TM

0.75 CME: This CME activity provides expert insights on selecting ADT, managing CV risk, and overcoming treatment disparities in patients with prostate cancer. Exp 3/13/2024

Improved Outcomes in Advanced Gastric and Colorectal Cancers | myCME

ANCC Contact Hour(s)

1.00 CNE: Learn about the pathogenesis, risks, screening, treatment options and management, including strategies to mitigate disparities of care, for both gastric and colorectal cancer. Exp 4/30/24

New Treatment of Paroxysmal Nocturnal Hemoglobinuria | myCME

AMA PRA Category 1 Credit(s)^TM

0.75 CME: Dr. Ilene Weitz takes a deep dive into recently published insights for treatment and management of this poorly understood hematologic disorder. Exp 6/15/24

Supporting Patients During AML Maintenance Therapy | myCME

ANCC Contact Hour(s)

1.00 CNE: Learn how to identify patients with AML who would benefit from maintenance therapy and how to apply collaborative management strategies, including those to mitigate disparities of care. Exp 4/30/24

Clinical Implications of HER2-targeted Therapy for mCRC | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.00 CME CE: The presence of HER2, a clinically actionable oncogenic driver, allows for the use of targeted therapy in almost 5% of CRC patients. Exp 8/21/24